Gastrointestinal stromal tumor
MONDO:0011719Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal (GI) tract, typically presenting in adults over the age of 40 (mean age 63), and only rarely in children, in various regions of the GI tract, most commonly the stomach or small intestine but also less commonly in the esophagus, appendix, rectum and colon. GISTs can be asymptomatic or present with various non-specific signs, depending on the location and size of tumor, such as loss of appetite, anemia, weight loss, fatigue, abdominal discomfort or fullness, nausea, vomiting, as well as an abdominal mass, blood in stool, and intestinal obstruction. GISTs can also be seen in familial syndromes such as Carney triad and neurofibromatosis type 1.
Also known as: GIST, Gastrointestinal Stromal Tumors, gastrointestinal stromal neoplasm, gastrointestinal stromal sarcoma, gastrointestinal stromal tumor, gastrointestinal stromal tumor (gist), gastrointestinal stromal tumor, familial, isolated cases, gastrointestinal stromal tumor, isolated cases
1540 clinical trials for this condition and its sub-types, 93 tagged with Gastrointestinal stromal tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Old drugs, new hope: imatinib combo tested for rare tumors
Disease control CompletedThis early-phase trial tested two cancer drugs—imatinib mesylate and cyclophosphamide—given daily by mouth to 26 people with rare, advanced tumors that had no standard treatment. The main goal was to find the safest dose of imatinib when combined with a fixed dose of cyclophospha…
Phase 1 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Cancer drug Imatinib's Long-Term safety tracked in ongoing patients
Disease control CompletedThis study looks at the long-term safety of imatinib, a daily pill for certain cancers like GIST and CML. It includes 250 patients who were already benefiting from imatinib in a previous Novartis trial and continue taking it. The main goal is to track side effects over time, with…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a Brain-Cancer drug take on a stubborn stomach tumor?
Disease control CompletedThis phase 2 trial is testing whether the chemotherapy drug temozolomide can shrink tumors in people with a rare type of gastrointestinal stromal tumor (GIST) that has a mutation in the SDH gene. Standard GIST treatments do not work for this subtype. Participants take temozolomid…
Phase 2 • Sponsor: Adam Burgoyne, MD, PhD • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug shows promise in controlling advanced GIST tumors
Disease control CompletedThis phase 4 trial tested the drug nilotinib in 34 adults with advanced GIST that could not be removed by surgery. The goal was to see how many patients had their tumors shrink or stay stable after 6 months. Researchers measured response using standard tumor scans. The study prov…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New targeted drug takes on stomach cancer in Head-to-Head trial
Disease control CompletedThis phase 2 trial compares two oral targeted drugs—ripretinib and sunitinib—in 108 people with advanced gastrointestinal stromal tumors (GIST) whose cancer has worsened on or who cannot tolerate imatinib. The main goal is to see which drug better delays cancer growth. Participan…
Phase 2 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Chemotherapy drug paclitaxel tested for Hard-to-Treat GIST
Disease control CompletedThis phase II trial tested the chemotherapy drug paclitaxel in 40 patients with advanced or metastatic gastrointestinal stromal tumor (GIST) whose cancer had stopped responding to three standard treatments: imatinib, sunitinib, and regorafenib. The study focused on patients with …
Phase 2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug shows promise for rare stomach cancer in chinese patients
Disease control CompletedThis study looked at how safe and effective the drug avapritinib is for Chinese patients with a rare type of stomach cancer called gastrointestinal stromal tumor (GIST). Researchers observed 61 patients in real-world clinics, not in a controlled lab setting. The goal was to track…
Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug NB003 tested in 258 patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…
Phase 1 • Sponsor: Ningbo Newbay Technology Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo shows promise for rare cancers
Disease control CompletedThis study tested a combination of two drugs—pembrolizumab (an immunotherapy) and cyclophosphamide (a chemotherapy)—in 129 people with advanced sarcomas that had spread or could not be removed by surgery. The goal was to see if the combination could shrink tumors or stop them fro…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo therapy shows promise for Hard-to-Treat gut cancer
Disease control CompletedThis study tested a combination of two drugs—avelumab (an immunotherapy) and axitinib (a targeted therapy)—in 58 adults with advanced gastrointestinal stromal tumor (GIST) that had worsened after standard treatments. The main goal was to see how many patients were still cancer-fr…
Phase 2 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Disease control
Last updated Jun 26, 2026 16:23 UTC
-
AI reads scans and slides to outsmart stomach cancer
Diagnosis CompletedThis study tested an artificial intelligence model that combines CT scans, digital pathology images, and patient history to improve diagnosis and risk prediction for gastrointestinal stromal tumors (GISTs). Researchers enrolled 300 patients with suspected stomach tumors. The AI a…
Sponsor: Qun Zhao • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Zinc and cream combo may stop painful side effect of cancer treatment
Symptom relief CompletedThis study tested whether taking zinc supplements and applying a strong steroid cream (clobetasol) can prevent or reduce hand-foot skin reaction, a common and painful side effect of the cancer drug regorafenib. About 150 patients starting regorafenib were split into three groups:…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 26, 2026 17:04 UTC
-
Nationwide registry maps the course of a rare stomach tumor
Knowledge-focused CompletedResearchers in Taiwan are building a nationwide registry of people diagnosed with gastrointestinal stromal tumors, a rare cancer of the digestive tract. The study collects details on how the tumors are found, their stage, the treatments patients receive, and how they fare over ti…
Sponsor: National Health Research Institutes, Taiwan • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can ultrasound predict cancer drug response earlier?
Knowledge-focused CompletedThis trial is testing whether contrast-enhanced ultrasound (CEUS) can reliably measure tumor blood flow in people with metastatic cancers like GIST, breast, kidney, colon, rectal, or melanoma. Participants will have two ultrasound scans before starting anti-angiogenic treatment, …
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Study aims to pinpoint ideal imatinib dose for GIST patients
Knowledge-focused CompletedThis completed study looked at 328 patients with intermediate or high-risk gastrointestinal stromal tumors (GISTs) who took imatinib after surgery. The goal was to find the best dose that balances effectiveness in preventing tumor return with the risk of side effects. Researchers…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
700 patients reviewed: are minimally invasive tumor removals effective Long-Term?
Knowledge-focused CompletedThis study looks back at 700 patients who had endoscopic treatment for gastrointestinal submucosal tumors at Xijing Hospital. Researchers want to know how often the tumors are completely removed, what complications occur, and whether the tumors come back over time. The goal is to…
Sponsor: Xijing Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Real-World GIST study reveals treatment patterns over 28 years
Knowledge-focused CompletedThis completed observational study looked at 492 patients with metastatic gastrointestinal stromal tumors (GIST) in France between 1990 and 2018. Researchers analyzed real-world treatment patterns, including which drugs were used and in what order, and how many patients got acces…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Real-World data on ripretinib for advanced GIST: what does it mean for patients?
Knowledge-focused CompletedThis completed observational study in Germany followed 10 patients with advanced gastrointestinal stromal tumor (GIST) who had already tried three or more prior treatments. Researchers tracked how ripretinib affected their quality of life and disease control in everyday clinical …
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC